NCT00046787View on ClinicalTrials.gov

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 30, 2002

Study Completion Date

February 28, 2003

Conditions
SCLCCarcinoma, Small Cell
Interventions
DRUG

OSI-211 (Liposomal Lurtotecan)

Trial Locations (10)

37920

Baptist Hospital Regional Cancer Ctr., Knoxville

80262

University of Colorado Health Sciences Center, Denver

85712

Arizona Clinical Research Center, Inc., Tucson

37232-6307

Vanderbilt Clinical Trials Office, Nashville

NG5 1PB

Nottingham City Hospital, Nottingham

CH63 4JY

Clatterbridge Centre for Oncology, Bebington

Unknown

Aberdeen Royal Infirmary, Aberdeen

SE1

Guys Hospital, London

M20 9BH

Christie Hospital, Manchester

NE4 6BE

Northern Centre for Cancer Research, Newcastle General Hospital, Newcastle upon Tyne

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00046787 - Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter